Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive color

Trial Details

NCT ID
NCT06824064
Phase
PHASE2
Sponsor
Riboscience, LLC.
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • RBS2418
  • Placebo
Locations (sample)
  • Newark, Delaware, United States|39.68372,-75.74966
  • Kingwood, Texas, United States|30.05691,-95.18349
  • San Juan, Puerto Rico|18.46633,-66.10572
  • Ho Chi Minh City, Ho Chi Minh City, Vietnam|10.82302,106.62965
  • Hà Nội, Vietnam|20.47366,106.02292

Key Eligibility Criteria

  • At least 18 years of age on the day of signing informed consent.
  • Male and female subjects with advanced, metastatic, progressive CRC who have received, been ineligible for, intolerant to, or declined all approved…
  • Have histologically or cytologically confirmed CRC diagnosis based on pathology report.
  • Willing to submit a pre-treatment tissue sample (archival, or fresh tissue if archival is not available).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →